The misuse and harms of gabapentin and pregabalin: call for evidence
Published 22 August 2025
© Crown copyright 2025
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/calls-for-evidence/the-misuse-and-harms-of-gabapentin-and-pregabalin/the-misuse-and-harms-of-gabapentin-and-pregabalin-call-for-evidence
About this call for evidence
The Advisory Council on the Misuse of Drugs (ACMD) is currently reviewing the evidence on the misuse and harms of pregabalin and gabapentin (gabapentinoids) in the United Kingdom.
The review aims to consider the evidence regarding the current use and harms of these compounds particularly in use with other substances and to assess the impact of recent changes in legislation regarding these compounds.
We welcome responses from as broad a spectrum of participants as possible and would be grateful if you could please circulate this call for evidence to colleagues and stakeholders.
The ACMD will use this evidence to assist in formulating advice to government.
The ACMD considers a wide range of evidence as part of its advice, including published literature, statistics, data from UK organisations and expert and stakeholder opinions.
If you have any questions or concerns about this call for evidence, please feel free to get in touch with us using the email address below.
How to respond
You can complete the questionnaire online, or return the downloadable version to the ACMD Secretariat at: acmd@homeoffice.gov.uk
Please respond by 11:59 pm on Monday 13 October.
Completing the questionnaire
Although your expertise may be better suited to tackling only a subset of the following questions, it would be helpful if you were to consider every question in the questionnaire.
If possible, please provide supporting evidence and references in your responses.
How we will use your information
Respondents should note that evidence submitted will inform the development of recommendations from the ACMD and could ultimately be published.
However, in the interest of confidentiality and protecting commercial interests, any information submitted will be non-attributable.
All data submitted in response to this call for evidence will be protected by the ACMD Secretariat in accordance with the UK General Data Protection Regulation (UK GDPR).
Furthermore, Section 43(1) of the Freedom of Information Act provides an exemption for information which is a trade secret, whilst Section 43(2) exempts information whose disclosure would, or would be likely to, prejudice the commercial interests of any person (an individual, a company, the public authority itself or any other legal entity).